Posted on 04/16/2020 5:27:17 PM PDT by SeekAndFind
Shares of Gilead Sciences Inc soared 15% on Thursday after a media report suggested that severe COVID-19 patients were positively responding to the drugmakers experimental treatment remdesivir.
A Chicago hospital treating COVID-19 patients with the antiviral medication as part of a trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, according to medical news website SThere
There are other trials being run concurrently at other institutions.
There are currently no approved treatments for COVID-19, the highly contagious respiratory illness caused by the novel coronavirus that has infected over 2 million people worldwide.
Gilead did not immediately respond to request for comment.
(Excerpt) Read more at reuters.com ...
OK, Good news, but here’s something to caution us (especially for those planning to own its stocks):
Unlike say, Hydroxychloroquine which has been tested in various places, Today’s reports are based on just ONE SITE and there is no placebo. In fact, the Phase 3 severe study reading out in the next 1-2 weeks has no placebo and is just 5 days versus 10 days of treatment.
Gilead still expects to report data from a controlled study in patients with severe disease by the end of April, with data from a study of patients with moderate disease coming in late May.
Game changer (maybe).
This is 21st Century’s equivalent of the Manhattan Project.
Bet mine script is more expensive than HCQ
HCQ for treatment early in the course of the disease or Remdesivir if it goes too far. Works for me but seriously what kind of name is Remdesivir? It doesn’t exactly stick in your head does it? How about CCP Virus Killer?
Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesnt have to be 10 days. We have very few that went out to 10 days, maybe three, she said.
Asked about the data, Eric Topol, director of the Scripps Research Translational Institute, described them as encouraging.
The severely hit patients are at such high-risk of fatality. So if its true that many of the 113 patients were in this category and were discharged, its another positive signal that the drug has efficacy,
Lol I just emailed Mr. Financial Guy and suggested he buy some. I’ll see how it goes.
RE: but seriously what kind of name is Remdesivir? It doesnt exactly stick in your head does it?
Easier to pronounce with less syllables than Hydroxychloroquine :)
Just curious, where did they publish the price of Remdesivir?
If I came down with this thing, I’d want to go with the ‘Trump pills’.
We’ve heard a lot of personal, as well as scientific, testimony to the efficacy of that.
Science isn’t always what it’s cracked-up to be; but human beings tend to know intimately the bodies within which they individually live.
What is the cost of the Gilead treatment? for the record I own the stock and have for about 10 years. Been waiting for the right time to sell it. It has not been this high in 36 months.
I saw the post on another thread. It didn’t have an active link. If it isn’t correct, ask to have the post pulled.
Remdesivir is an IV (not oral) drug and isnt on label for any indication. So it cannot have a price yet. My guess is that Gilead will feel obliged to make it somewhat affordable for mass use during a pandemic. Further, all insurances will likely cover its use for COVID-19.
1) Remdesivir is not currently for sale and it therefore has no price.
2) Its not a pill, its given IV.
3) Word on the street - results are spectacular.
It is an available drug.
Not exactly getting all the best minds in the world together to save the world.
As I said on the other thread. This has got a big chance once they get their study finished and published.
Good for Gilead. More trials, please.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.